Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer

Legend Biotech installs a permanent CEO while keeping Alan Bash focused on leading the CARVYKTI franchise.

Rhea-AI Summary

Legend Biotech (LEGN) has appointed Ingrid Zhang as Chief Executive Officer, effective September 15, 2026, following a Board-led search process.

Zhang succeeds Alan Bash, who has served as Interim CEO since July 2026 and will return to his position as President, CARVYKTI. She most recently served as Chief Commercial Officer for Novartis International, and previously held senior roles at AstraZeneca, Pfizer, and McKinsey & Company, bringing extensive global commercial and operational experience. The Board describes Zhang as the right leader for the company’s next phase of growth and expresses confidence in her ability to advance its cell therapy mission.

Legend Biotech highlights continued execution of its strategic priorities during the leadership transition and reiterates its focus on CARVYKTI, a CAR-T therapy for relapsed or refractory multiple myeloma developed with Johnson & Johnson, and on advancing its broader cell therapy pipeline.

Positive

• Ingrid Zhang appointed CEO with effect from September 15, 2026, providing permanent leadership after an interim period

Negative

• None.

Argus 15 min delay

-3.94% vs previous close $17.80 last price 2.7x rel. volume Open Argus

Details

Market Reaction – LEGN

$17.54 $19.02 Day Range

$3.46B Market Cap

Following this news, LEGN has declined 3.94%, reflecting a moderate negative market reaction. Our momentum scanner has triggered 28 alerts so far, indicating elevated trading interest and price volatility. The stock is currently trading at $17.80. Trading volume is elevated at 2.7x the average, suggesting increased selling activity.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Market Context

The -13.28% reaction to the Jul 27, 2026 interim-CEO appointment provided a directly comparable lead...

Analysis

The -13.28% reaction to the Jul 27, 2026 interim-CEO appointment provided a directly comparable leadership-transition datapoint; this announcement advanced that transition by naming a permanent CEO effective September 15, 2026.

Key Figures

CEO appointment effective date: September 15, 2026

CEO appointment effective date

September 15, 2026

Ingrid Zhang appointed Chief Executive Officer

Historical Context

1 past event · Latest: Jul 27

1 event

1. Jul 27

   CEO transition

   24h Move

   -13.3%

   Board appointed Alan Bash interim CEO after Ying Huang's resignation.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

cell therapy, car-t cell therapy, multiple myeloma

3 terms

cell therapy medical

"Legend Biotech, a global leader in cell therapy"

Cell therapy uses living human or animal cells as the medicine: cells are collected, sometimes grown or altered, and then given to a patient to repair, replace, or boost damaged tissue or immune function. For investors, cell therapies can transform markets because they may offer one-time or highly effective treatments that command premium prices, but they also carry high development, manufacturing and regulatory costs and commercial risks, like building a custom factory rather than making a simple product.

car-t cell therapy medical

"at the forefront of the CAR-T cell therapy revolution"

A therapy that takes a patient’s own immune cells, reprograms them in a lab to recognize and attack specific disease cells, then returns them to the body—think of training and equipping a guard dog to find a particular intruder. Investors care because these treatments can offer dramatic clinical benefits, carry high development and manufacturing costs, and create new, often lucrative markets if they receive regulatory approval and payer support.

multiple myeloma medical

"for relapsed or refractory multiple myeloma"

A cancer of the blood that starts in plasma cells, the immune system’s antibody-producing cells in bone marrow. It behaves like a factory where the workers go rogue, crowding out healthy cells and causing bone damage, anemia and infections; treatments and trial results can sharply affect drug sales, regulatory approvals and company valuations, so progress or setbacks are closely watched by investors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Ingrid Zhang, an accomplished global biopharmaceutical leader, joins Legend Biotech following a comprehensive Board-led search process

BRIDGEWATER, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) ("Legend Biotech" or the "Company"), a global leader in cell therapy, today announced that its Board of Directors has appointed Ingrid Zhang as Chief Executive Officer, effective September 15, 2026. Ingrid Zhang succeeds Alan Bash, who has served as Interim Chief Executive Officer since July 2026 and will resume his role as President, CARVYKTI.

Ingrid Zhang is an accomplished global biopharmaceutical executive with deep experience leading commercial organizations, driving business growth, and advancing innovative medicines. Most recently, she served as Chief Commercial Officer for Novartis International. During her tenure at Novartis, she also led the company's China business and innovative medicines organization. Earlier in her career, she held leadership positions at AstraZeneca, Pfizer, and McKinsey & Company, bringing a combination of global commercial expertise, operational leadership, and strategic insight to Legend Biotech.

"It is a privilege to join Legend Biotech at an important moment in the Company's growth," said Ingrid Zhang, Chief Executive Officer of Legend Biotech. "Legend Biotech has established itself as a global leader in cell therapy through its commitment to scientific innovation, operational excellence, and transforming outcomes for patients. I look forward to working with the talented team at Legend to build on this strong foundation, advance our pipeline, expand our impact, and execute on our long-term growth strategy."

"Following a comprehensive search process, the Board concluded that Ingrid is the right leader to guide Legend Biotech through its next phase of growth," said Frank Zhang, EMBA, Ph.D., Chairman of the Board of Legend Biotech. "As a highly respected industry executive, Ingrid brings strategic vision, operational discipline, and experience leading complex global businesses. The Board is confident she is well-positioned to advance our mission of transforming patient care through cell therapy. We thank Alan Bash for his strong leadership as Interim CEO and are delighted to welcome Ingrid to Legend Biotech."

"Throughout this transition, our team has continued to execute against our strategic priorities with focus across the business," said Alan Bash, President, CARVYKTI. "The commitment and expertise of colleagues around the world have positioned Legend Biotech for its next chapter. The leadership team and I look forward to partnering closely with Ingrid as we continue executing our strategy and delivering meaningful impact for patients."

ABOUT LEGEND BIOTECH
With over 3,000 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. Legend Biotech is at the forefront of the CAR-T cell therapy revolution with CARVYKTI^®, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the United States, Legend Biotech is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, Legend Biotech plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.

Learn more at https://legendbiotech.com and follow us on X and LinkedIn.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Legend Biotech’s plans to advance its pipeline, expand its impact, and execute on its long-term growth strategy; Legend Biotech’s plans to continue advancing CARVYKTI and to deliver meaningful impact for patients and sustained growth; Legend Biotech’s expectations regarding the leadership transition and the anticipated contributions of its new Chief Executive Officer; and Legend Biotech’s plans to drive future innovation across its pipeline. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend Biotech’s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by our third-party partners; uncertainties arising from challenges to Legend Biotech’s patent or other proprietary intellectual property protection, including the uncertainties involved in the U.S. litigation process; government, industry, and general product pricing and other political pressures; as well as the other factors discussed in the "Risk Factors" section of Legend Biotech’s Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 10, 2026. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this press release as anticipated, believed, estimated, or expected. Any forward-looking statements contained in this press release speak only as of the date of this press release. Legend Biotech specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

INVESTOR CONTACT:
Caroline Paul
Tel: 973-650-5832
investor@legendbiotech.com

PRESS CONTACT:
Kim Fox
Tel: (848) 388-8445
media@legendbiotech.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What role will Alan Bash have after the CEO transition?

Alan Bash will end his service as Interim Chief Executive Officer and resume his prior role as President, CARVYKTI, continuing to focus on that franchise.

What industry experience does Ingrid Zhang bring to Legend Biotech?

Ingrid Zhang most recently served as Chief Commercial Officer for Novartis International. She also led Novartis’ China business and innovative medicines organization, and previously held leadership positions at AstraZeneca, Pfizer, and McKinsey & Company, combining global commercial, operational, and strategic experience.

How does Legend Biotech describe its business and scale?

Legend Biotech describes itself as the largest standalone cell therapy company, with over 3,000 employees, focused on treatments that change cancer care and on building an end-to-end cell therapy business centered in the United States.

What is CARVYKTI and how is it positioned in Legend Biotech’s portfolio?

CARVYKTI is described as a one-time CAR-T cell therapy for relapsed or refractory multiple myeloma, which Legend Biotech develops and markets with collaborator Johnson & Johnson. The company highlights efforts to maximize CARVYKTI’s patient access and therapeutic potential as a core part of its platform for future cell therapy innovation.